Where does Ripple Therapeutics Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Ripple Therapeutics Corporation ranks #37,254 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Ripple Therapeutics Corporation hold?

Ripple Therapeutics Corporation holds 7 US utility patents granted between 2020 and 2023, spanning 5 technology areas.

What is Ripple Therapeutics Corporation's Innovation Score?

Ripple Therapeutics Corporation has an Innovation Score of 34.1 out of 100 (46th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Ripple Therapeutics Corporation focus on?

Ripple Therapeutics Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 6 patents, ranking #2,984 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is Ripple Therapeutics Corporation's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Ripple Therapeutics Corporation.

What does claim depth mean for Ripple Therapeutics Corporation's patents?

Ripple Therapeutics Corporation's patents average 23.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Ripple Therapeutics Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Ripple Therapeutics Corporation

USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2020–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Ripple ranks #37,254 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.

#37,254
of 49,997 US assignees by volume: 46th percentile
by Innovation Score (34.1/100): 23.3
avg claims per patent

USPTO PatentsView assignee plate

Corpus R37254 · Foreign Corporation #37,254 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #37,254/49,997
PHOTO-FINISH Rhombus Energy…
CPC-NARROW A61P · 5 areas
INNOV-THIN 34.1/100
CLAIMS-DENSE 23.3 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2023 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Rhombus Energy Solutions, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Ripple’s 34.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (21%) Velocity 5.0 pts (15%) Breadth 7.9 pts (23%) Claim depth 14.0 pts (41%)

Qualcomm Incorporated · highest

85
Ripple Therapeutics · this assignee

34
3D Lighting… · lowest

7

What this shows Ripple's Innovation Score is 34.1/100 (46th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Ripple?

Each dot is one of Ripple’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Ripple’s own 23.3 claims/patent is ABOVE the 12.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Ripple vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Ripple's grants concentrate

Ripple Therapeutics Corporation is a focused PatentsView assignee: 5 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2023. By volume, Ripple sits between Rhombus Energy Solutions, Inc. and RMZ Development LLC.

Ripple's three-year grant acceleration

Ripple Therapeutics Corporation shows 3 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Rhombus Energy So…

7
Ridge

7
Ridley USA

7
Ripelocker

7
Rivertop Renewabl…

7
RKW SE

7
RL Industry

7
RMZ Development

7
Ripple Therapeuti… ◀

7

What this shows Ripple holds 7 patents at rank #37,178, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ripple

By rank, the assignees closest to #37,178 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Ripple's primary technology class.

Ripple's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 46th percentile higher than 46% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Ripple Therapeutics Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	28.6%
2021	2	28.6%
2022	2	28.6%
2023	1	14.3%

Which technologies does Ripple Therapeutics Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

C07J - Steroids 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Ripple Therapeutics Corporation's patent record in context - here's where to go next.

Ripple Therapeutics Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #37,254 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Ripple Therapeutics Corporation against Rhombus Energy Solutions, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.